Phosphatidylethanolamine-binding protein 1 (Raf-1 kinase inhibitor protein) (RKIP)

Phosphatidylethanolamine-binding protein 1, widely known as Raf-1 kinase inhibitor protein (RKIP), is a small, evolutionarily conserved protein that plays a critical role as a modulator of several key intracellular signaling cascades (UniProt P30086). It is best characterized for its ability to bind to Raf-1, thereby preventing the phosphorylation and subsequent activation of MEK and the downstream ERK/MAPK pathway (Yeung et al., 1999, PMID: 10490620). Beyond the MAPK pathway, RKIP also negatively regulates the NF-kappaB signaling pathway and modulates G protein-coupled receptor (GPCR) signaling by inhibiting G protein-coupled receptor kinase 2 (GRK2) (Yeung et al., 2005, PMID: 15659504). In the context of oncology, RKIP is recognized as a potent metastasis suppressor, and its expression is frequently downregulated or lost in various advanced cancers, correlating with poor clinical outcomes and resistance to chemotherapy (Fu et al., 2003, PMID: 12853971). Because of its role in suppressing tumor progression, therapeutic strategies often focus on restoring RKIP expression or mimicking its function to sensitize cancer cells to treatment. Additionally, RKIP has been implicated in other pathological conditions, including neurodegenerative diseases like Alzheimer's and inflammatory disorders, making it a versatile target for drug discovery (Al-Mulla et al., 2013, PMID: 23460540).

Other names

Raf kinase inhibitor proteinPEBP1PEBPPBPNeuropolypeptide h3Prostatic-binding protein

RKIP acts as a competitive inhibitor of the Raf-1/MEK interaction, preventing the phosphorylation of MEK by Raf-1. It also inhibits the NF-kappaB pathway by interacting with and inhibiting NIK and IKK, and modulates GPCR signaling by inhibiting GRK2-mediated receptor desensitization (PMID: 10490620, 15659504).